Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMEC/VI on Exercise Endurance in COPD
NCT02275052Phase 4Completed
- Sponsor
- GSK
- Start
- Jan 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Anoro Ellipta in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Exercise Endurance Time at Week 12. Started Jan 2015; status: completed.
02
Drugs
Anoro Ellipta
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02275052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02275052.